HomeCompareCSPCY vs MO

CSPCY vs MO: Dividend Comparison 2026

CSPCY yields 2.60% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSPCY wins by $860.3K in total portfolio value
10 years
CSPCY
CSPCY
● Live price
2.60%
Share price
$4.61
Annual div
$0.12
5Y div CAGR
65.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$938.0K
Annual income
$630,692.19
Full CSPCY calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — CSPCY vs MO

📍 CSPCY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSPCYMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSPCY + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSPCY pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSPCY
Annual income on $10K today (after 15% tax)
$221.26/yr
After 10yr DRIP, annual income (after tax)
$536,088.36/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, CSPCY beats the other by $511,465.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSPCY + MO for your $10,000?

CSPCY: 50%MO: 50%
100% MO50/50100% CSPCY
Portfolio after 10yr
$507.8K
Annual income
$329,830.37/yr
Blended yield
64.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

CSPCY
No analyst data
Altman Z
6.5
Piotroski
5/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSPCY buys
0
MO buys
11
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$MO▲ Buy$1,000 - $15,0002025-08-04
Sheri Biggs🏢 House$MO▼ Sell$1,001 - $15,0002025-03-19
Pete Sessions🏢 House$MO▼ Sell$1,001 - $15,0002024-09-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-03-20
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-02-13
Virginia Foxx🏢 House$MO▼ Sell$1,001 - $15,0002024-01-16
Virginia Foxx🏢 House$MO▲ Buy$1,001 - $15,0002024-01-11
Ro Khanna🏢 House$MO▼ Sell$1,001 - $15,0002024-01-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-01-10
Virginia Foxx🏢 House$MO▼ Sell$15,001 - $50,0002024-01-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSPCYMO
Forward yield2.60%6.27%
Annual dividend / share$0.12$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR65.6%22.6%
Portfolio after 10y$938.0K$77.7K
Annual income after 10y$630,692.19$28,968.54
Total dividends collected$886.9K$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CSPCY vs MO ($10,000, DRIP)

YearCSPCY PortfolioCSPCY Income/yrMO PortfolioMO Income/yrGap
1← crossover$11,131$431.06$10,558$768.31+$573.00CSPCY
2$12,653$742.60$11,352$1,015.87+$1.3KCSPCY
3$14,845$1,306.42$12,482$1,367.86+$2.4KCSPCY
4$18,256$2,372.19$14,103$1,883.39+$4.2KCSPCY
5$24,049$4,515.02$16,472$2,664.91+$7.6KCSPCY
6$34,938$9,205.02$20,024$3,897.79+$14.9KCSPCY
7$58,080$20,696.38$25,537$5,933.74+$32.5KCSPCY
8$115,393$53,247.73$34,478$9,476.77+$80.9KCSPCY
9$287,202$163,731.68$49,776$16,022.63+$237.4KCSPCY
10$937,999$630,692.19$77,699$28,968.54+$860.3KCSPCY

CSPCY vs MO: Complete Analysis 2026

CSPCYStock

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Full CSPCY Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this CSPCY vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSPCY vs SCHDCSPCY vs JEPICSPCY vs OCSPCY vs KOCSPCY vs MAINCSPCY vs PMCSPCY vs BTICSPCY vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.